SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

NCT03417895 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: SHR-1210
DRUG: Apatinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.